Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Anticoagulant therapy is generally recommended for all patients presenting with acute
symptomatic splanchnic vein thrombosis, starting with either low-molecular weight heparin
(LMWH) or unfractionated heparin and continuing with the vitamin K antagonists in most
patients. Rivaroxaban is approved for the treatment of deep vein thrombosis and pulmonary
embolism, but no studies have assessed the safety of rivaroxaban in the setting of splanchnic
vein thrombosis. The investigators aim to collect prospective information on the safety of
rivaroxaban in a pilot cohort of 100 patients with acute splanchnic vein thrombosis without
liver cirrhosis.